Leishmaniasis: current status of available drugs and new potential drug targets
Asian Pacific Journal of Tropical Medicine
;
(12): 485-497, 2012.
Artigo
em Inglês
| WPRIM
| ID: wpr-819646
ABSTRACT
The control of Leishmania infection relies primarily on chemotherapy till date. Resistance to pentavalent antimonials, which have been the recommended drugs to treat cutaneous and visceral leishmaniasis, is now widespread in Indian subcontinents. New drug formulations like amphotericin B, its lipid formulations, and miltefosine have shown great efficacy to treat leishmaniasis but their high cost and therapeutic complications limit their usefulness. In addition, irregular and inappropriate uses of these second line drugs in endemic regions like state of Bihar, India threaten resistance development in the parasite. In context to the limited drug options and unavailability of either preventive or prophylactic candidates, there is a pressing need to develop true antileishmanial drugs to reduce the disease burden of this debilitating endemic disease. Notwithstanding significant progress of leishmanial research during last few decades, identification and characterization of novel drugs and drug targets are far from satisfactory. This review will initially describe current drug regimens and later will provide an overview on few important biochemical and enzymatic machineries that could be utilized as putative drug targets for generation of true antileishmanial drugs.
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Assunto principal:
Pentamidina
/
Fosforilcolina
/
Poliaminas
/
Inibidores de Proteases
/
Esteróis
/
Compostos de Sulfidrila
/
Paromomicina
/
Leishmaniose
/
Anfotericina B
/
Gluconato de Antimônio e Sódio
Limite:
Humanos
Idioma:
Inglês
Revista:
Asian Pacific Journal of Tropical Medicine
Ano de publicação:
2012
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS